NCT04847050 2024-08-27A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor TherapyNational Institutes of Health Clinical Center (CC)Phase 2 Completed19 enrolled 18 charts